[{"orgOrder":0,"company":"Alpha Cancer Technologies","sponsor":"AbSci","pharmaFlowCategory":"D","therapeuticArea":"Immunology","country":"U.S.A","productType":"Protein","year":"2020","type":"Licensing Agreement","leadProduct":"Recombinant Human Alpha-Fetoprotein","moa":"Alpha-fetoprotein receptor","graph1":"Immunology","graph2":"Phase I","graph3":"Alpha Cancer Technologies","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Alpha Cancer Technologies \/ Alpha Cancer Technologies","highestDevelopmentStatusID":"6","companyTruncated":"Alpha Cancer Technologies \/ Alpha Cancer Technologies"}]

Find Clinical Drug Pipeline Developments & Deals by Alpha Cancer Technologies

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          ChemOutsourcing
                          Not Confirmed
                          ChemOutsourcing
                          Not Confirmed

                          Details : Under the terms of the agreement AbSci will prepare the hAFP producing E. coli strain for transfer to Alpha Cancer Technologies' CMO of choice for commercial production.

                          Product Name : Undisclosed

                          Product Type : Protein

                          Upfront Cash : Undisclosed

                          July 22, 2020

                          Lead Product(s) : Recombinant Human Alpha-Fetoprotein

                          Therapeutic Area : Immunology

                          Highest Development Status : Phase I

                          Recipient : AbSci

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank